10-Q: OS Therapies Reports Q3 2024 Results, Highlights IPO and Clinical Trial Progress

OS Therapies reported its financial results for the third quarter of 2024, highlighting its recent IPO and ongoing clinical trial for Osteosarcoma.

Summary

• OS Therapies, a clinical-stage biopharmaceutical company, released its financial results for the quarter ended September 30, 2024.
• The company is focused on developing treatments for Osteosarcoma and other solid tumors.
• A key development is the ongoing clinical trial for OST-HER2, which completed full enrollment of 41 patients in October 2023.
• Topline results from this trial are expected in the fourth quarter of 2024.
• The company completed its initial public offering (IPO) on August 2, 2024, raising $6.4 million in gross proceeds.
• All outstanding convertible notes were converted into common stock as part of the IPO.
• The company reported a net loss of $2.87 million for the three months ended September 30, 2024, and a net loss of $5.89 million for the nine months ended September 30, 2024.
• Research and development expenses were $1.21 million for the quarter and $1.97 million for the nine-month period.
• General and administrative expenses were $1.23 million for the quarter and $1.88 million for the nine-month period.
• As of September 30, 2024, the company had cash of $1.86 million.
• The company is seeking to raise additional capital through a public or private financing of equity.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. The company has made progress with its clinical trial and IPO, but it is also facing significant financial challenges and has identified weaknesses in its internal controls. The need for additional capital and the ongoing losses are concerning, but the potential of the company's technology and the upcoming clinical trial results provide some optimism.

Positives

• The successful completion of the IPO provides the company with additional capital.
• The full enrollment of the Phase 2 clinical trial for OST-HER2 is a significant milestone.
• The company is actively working towards regulatory approval for OST-HER2 in 2025.
• The company has a next-generation antibody-drug conjugate platform (OST-tADC) in development.

Negatives

• The company has incurred net losses since its inception and has negative operating cash flows.
• The company's ability to continue operations is dependent on obtaining additional capital.
• The company's disclosure controls and procedures were deemed not effective due to lack of segregation of duties and insufficient written policies.
• The company has a significant accumulated deficit of $35.4 million as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is uncertain due to its history of net losses and negative operating cash flows.
• The company is dependent on raising additional capital to fund its operations.
• There is no guarantee that the company will be successful in its efforts to obtain regulatory approval for OST-HER2.
• The company's disclosure controls and procedures are not effective, which could lead to errors in financial reporting.
• The company faces risks associated with clinical trials, including the possibility of unfavorable results or delays.
• The company is subject to risks associated with the development and commercialization of new pharmaceutical products.

Future Outlook

The company expects topline results from its OST-HER2 clinical trial in the fourth quarter of 2024 and intends to seek regulatory approval for OST-HER2 for the prevention of metastases in Osteosarcoma in 2025. The company also intends to evaluate OST-HER2's potential use in other solid tumors and to investigate clinical indications for OST-tADC in Osteosarcoma and other solid tumors. The company has the right to sell up to $15 million worth of shares of common stock to Square Gate Capital Master Fund, LLC-Series 3 over the next 24 months.

Management Comments

• The company is focused on the identification, development, and commercialization of treatments for Osteosarcoma and other related diseases.
• The company's mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
• The company is currently seeking to answer the call for new treatments that will prevent metastasis and the recurrence of metastases with its lead core product candidate OST-HER2.
• The company intends to investigate clinical indications for OST-tADC in Osteosarcoma and other solid tumors.

Industry Context

The company operates in the biopharmaceutical industry, specifically focusing on oncology. The company's focus on Osteosarcoma, a rare cancer with limited treatment options, positions it to address an unmet medical need. The company's development of immunotherapies and antibody-drug conjugates aligns with current trends in cancer treatment. The company is not aware of any competing adjuvant therapy for Osteosarcoma to be tested in children that is further along in the development process than OST-HER2.

Comparison to Industry Standards

• OS Therapies is a clinical-stage company, which is typical for companies in the biopharmaceutical industry focused on drug development.
• The company's focus on a rare cancer like Osteosarcoma is a niche strategy, which can be both advantageous and risky.
• The company's reliance on external funding through convertible notes and an IPO is common for early-stage biotech companies.
• The company's research and development expenses are typical for a company in its stage of development.
• The company's net losses are also typical for a pre-revenue biotech company.
• The company's cash position of $1.86 million is relatively low for a company with ongoing clinical trials and research programs, indicating a need for additional funding.
• The company's reliance on licensing agreements with companies like Advaxis and BlinkBio is a common strategy in the biotech industry to access proprietary technologies.
• The company's use of contract research organizations (CROs) like George Clinical is a standard practice in the industry to manage clinical trials.
• The company's convertible debt structure is a common financing method for early-stage biotech companies, but it can be complex and dilutive.
• The company's recent IPO is a significant step towards accessing public capital markets, which is a common goal for biotech companies.

Legal Proceedings

• The company settled an arbitration proceeding with Noble Capital Markets, Inc. in September 2024, in exchange for $50,000 and 320,033 shares of common stock.

Related Party Transactions

• The company had a payroll payable to the CEO of $10,000 as of September 30, 2024.
• The company has a bill in accounts payable of $23,252 for the period ended September 30, 2024 to Shore Accountants MD Inc., an outside accounting firm that handles payroll and bookkeeping and is 100% owned by the CFO.
• Ted Search and John Ciccio, members of the Board, held convertible notes that were converted into common stock upon the IPO.

Stakeholder Impact

• Shareholders: The company's financial performance and the success of its clinical trials will directly impact shareholder value.
• Employees: The company's ability to secure funding and achieve its goals will affect job security and opportunities.
• Patients: The company's development of new treatments for Osteosarcoma could have a significant positive impact on patients with this disease.
• Creditors: The company's ability to repay its debts is dependent on its financial performance and ability to raise capital.
• Suppliers: The company's ability to pay its suppliers is dependent on its financial performance and ability to raise capital.

Next Steps

• The company expects topline results from its OST-HER2 clinical trial in the fourth quarter of 2024.
• The company intends to seek regulatory approval for OST-HER2 for the prevention of metastases in Osteosarcoma in 2025.
• The company will continue to evaluate OST-HER2's potential use in other solid tumors.
• The company will investigate clinical indications for OST-tADC in Osteosarcoma and other solid tumors.
• The company will seek to raise additional capital through a public or private financing of equity.
• The company will work to improve its disclosure controls and procedures.

Key Dates

Keywords

Osteosarcoma, Immunotherapy, Clinical Trial, IPO, OST-HER2, OST-tADC, Biopharmaceutical, Drug Development, HER2, Metastasis